12:00 AM
 | 
Apr 25, 2011
 |  BioCentury  |  Analyst Picks & Changes

Analyst Picks & Changes

Analyst Picks & Changes

Company Bank Analyst Coverage Opinion Wk chg 4/21 cls
Acorda Therapeutics Inc. (NASDAQ:ACOR) RBC Capital Markets Michael Yee Price target Market outperform -5% $27.56
Yee raised his target to $38 from $32 after the U.S. Patent and Trademark Office allowed a patent application on the composition of Acorda's multiple sclerosis drug Ampyra dalfampridine. The claims of the application, No. 11/010,828, relate to methods to improve walking in MS patients by administering 10 mg sustained-release 4-aminopyridine (see B8). Yee believes the application's claims are broad in scope and should provide protection against other sustained formulations of the compound until 2026, when the patent would expire. Ampyra's current patents expire in 2011 and 2013. Acorda has rights to Ampyra from Elan Corp. plc (NYSE:ELN).
Alexion Pharmaceuticals Inc. (NASDAQ:ALXN)

Read the full 802 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >